Trial Profile
A Randomized, Double-masked, Vehicle-controlled Study of LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Licaminlimab (Primary)
- Indications Dry eyes
- Focus Proof of concept; Therapeutic Use
- Sponsors Alcon
- 23 Aug 2022 According to an Oculis media release, results have been published by the Clinical Ophthalmology journal.
- 23 Aug 2022 Results published in Oculis Pharma Media Release
- 11 May 2021 Results published in an Oculis media release.